Carlsquare advised enua Pharma GmbH, one of the top-3-providers of medical cannabis in the German market, on structuring a 25 million euros financing package with Deutsche Bank to support further growth. The transaction marks another Carlsquare deal in the medical cannabis sector.
enua Pharma GmbH (“enua”) is a leading provider of medical cannabis in the rapidly growing German market. Founded in 2019 and headquartered in Cologne, the company pursues the vision of further developing the treatment of chronic pain, neurological disorders and spasticity and enabling patients to gain improved access to relevant therapies. Due to improved infrastructure for prescriptions and the growing recognition of medical cannabis as a treatment option, enua has experienced strong growth in recent years.
The debt financing enables enua to strengthen its working-capital management in a targeted manner, diversify its customer base through the build-out of an additional brand, and simultaneously continue to execute its inorganic growth strategy – including the planned acquisition of sales and distribution licenses in the United Kingdom. Thereby, enua will position itself more strongly within the highly regulated ecosystem of patients, physicians, and pharmacies, increase the resilience of its business model, and deepen its value chain.
Amid a dynamic market environment in the medical cannabis sector that is subject to ongoing regulatory debate, the transaction underlines the increasing relevance of financing structures for scalability and resilient growth and creates the basis to accelerate enua’s growth strategy in the future also through further acquisitions.
“This financing is not just capital. It is a clear signal of confidence – in our work, our strong and profitable growth, our team, and in the conviction that medical cannabis deserves the same professional standards as any other part of healthcare.” – Albert Schwarzmeister, CEO & Shareholder, enua Pharma GmbH
Carlsquare acted as the exclusive financial advisor to enua Pharma GmbH.
